0001193125-26-193145.txt : 20260429 0001193125-26-193145.hdr.sgml : 20260429 20260429204412 ACCESSION NUMBER: 0001193125-26-193145 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260429 FILED AS OF DATE: 20260429 DATE AS OF CHANGE: 20260429 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FMR LLC CENTRAL INDEX KEY: 0000315066 ORGANIZATION NAME: STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-43251 FILM NUMBER: 26919402 BUSINESS ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6175706339 MAIL ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 FORMER NAME: FORMER CONFORMED NAME: FMR CORP DATE OF NAME CHANGE: 19920717 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Avalyn Pharma Inc. CENTRAL INDEX KEY: 0001540171 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 452463191 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 105 W FIRST ST. CITY: BOSTON STATE: MA ZIP: 02127 BUSINESS PHONE: (206) 707-0340 MAIL ADDRESS: STREET 1: 105 W FIRST ST. CITY: BOSTON STATE: MA ZIP: 02127 FORMER COMPANY: FORMER CONFORMED NAME: Genoa Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20120120 3 1 ownership.xml 3 X0607 3 2026-04-29 0 0001540171 Avalyn Pharma Inc. AVLN 0000315066 FMR LLC false 245 SUMMER STREET BOSTON MA 02210 false false true true See Remark 1 Series A Preferred Stock Common Stock 727585 I F-Prime Capital Partners Healthcare Fund V LP Series B Preferred Stock Common Stock 80291 I F-Prime Capital Partners Healthcare Fund V LP Series C-1 Preferred Stock Common Stock 872868 I F-Prime Capital Partners Healthcare Fund V LP Series C-2 Preferred Stock Common Stock 225843 I F-Prime Capital Partners Healthcare Fund V LP Series D Preferred Stock Common Stock 377948 I F-Prime Capital Partners Healthcare Fund V LP The Series A Preferred Shares, Series B Preferred Shares, Series C-1 Preferred Shares, Series C-2 Preferred Shares, and Series D Preferred Shares are convertible on a 1-for-1 basis into the number of shares of Common Stock as shown in column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration, and have no expiration date. Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: The general partner of F-Prime Capital Partners Healthcare Fund V LP is F-Prime Capital Partners Healthcare Advisors Fund V LP (FPCPHA). FPCPHA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. /s/ Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson 2026-04-29